Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prothena CEO Dale Schenck Dies From Pancreatic Cancer

Executive Summary

Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.

You may also be interested in...

Prothena Sees Potential In Targeting Amyloid, Validated By Biogen

Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs. 

Lilly's Leap Tests Investors' Faith In Solanezumab

Eli Lilly & Co. concedes that its revised primary endpoint for the ongoing Phase III clinical trial testing solanezumab in mild Alzheimer's patients goes against US FDA and European Medicines Agency (EMA) requirements, but the company is "hopeful" the change still will support regulatory approvals.

JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure

It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts